

23 - References

References

894 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 11 References

1. Kroon LA. Drug interactions with smoking. *Am J Health Syst Pharm* 2007; 64:1917-1921.
2. Scherf-Clavel M, et al. Analysis of smoking behavior on the pharmacokinetics of antidepressants and antipsychotics: evidence for the role of alternative pathways apart from CYP1A2. *Int Clin Psychopharmacol* 2019; 34:93-100.
3. Desai HD, et al. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. *CNS Drugs* 2001; 15:469-494.
4. Faber MS, et al. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. *Clin Pharmacol Ther* 2004; 76:178-184.
5. Servier Laboratories Limited. Summary of product characteristics. Valdoxan (agomelatine). 2021; <https://www.medicines.org.uk/emc/medicine/21830>.
6. Miller LG. Recent developments in the study of the effects of cigarette smoking on clinical pharmacokinetics and clinical pharmacodynamics. *Clin Pharmacokinet* 1989; 17:90-108.
7. Goff DC, et al. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. *Am J Psychiatry* 1992; 149:1189-1194.
8. Haring C, et al. Influence of patient-related variables on clozapine plasma levels. *Am J Psychiatry* 1990; 147:1471-1475.
9. Diaz FJ, et al. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. *Pharmacopsychiatry* 2008; 41:81-91.
10. Tsuda Y, et al. Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine. *BMJ Open* 2014; 4:e004216.
11. Flanagan RJ, et al. Effect of cigarette smoking on clozapine dose and on plasma clozapine and N-desmethylclozapine (norclozapine) concentrations in clinical practice. *J Clin Psychopharmacol* 2023; 43:514-519.
12. Tsukahara M, et al. Effect of smoking habits and concomitant valproic acid use on relapse in patients with treatment-resistant schizophrenia receiving clozapine: a 1-year retrospective cohort study. *Acta Psychiatr Scand* 2023; 148:437-446.
13. Augustin M, et al. Effect of fluvoxamine augmentation and smoking on clozapine serum concentrations. *Schizophr Res* 2019; 210:143-148.
14. Qurashi I, et al. Changes in smoking status, mental state and plasma clozapine concentration: retrospective cohort evaluation. *BJPsych Bull* 2019; 43:271-274.
15. Fric M, et al. The influence of smoking on the serum level of duloxetine. *Pharmacopsychiatry* 2008; 41:151-155.

16. Augustin M, et al. Differences in duloxetine dosing strategies in smoking and nonsmoking patients: therapeutic drug monitoring uncovers the impact on drug metabolism. *J Clin Psychiatry* 2018; 79:17m12086.
17. Scherf-Clavel M, et al. Smoking is associated with lower dose-corrected serum concentrations of escitalopram. *J Clin Psychopharmacol* 2019; 39:485–488.
18. Ereshefsky L, et al. Effects of smoking on fluphenazine clearance in psychiatric inpatients. *Biol Psychiatry* 1985; 20:329–332.
19. Spigset O, et al. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. *Clin Pharmacol Ther* 1995; 58:399–403.
20. Jann MW, et al. Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. *Psychopharmacology (Berl)* 1986; 90:468–470.
21. Shimoda K, et al. Lower plasma levels of haloperidol in smoking than in nonsmoking schizophrenic patients. *Ther Drug Monit* 1999; 21:293–296.
22. Takahashi LH, et al. Effect of smoking on the pharmacokinetics of inhaled loxapine. *Ther Drug Monit* 2014; 36:618–623.
23. Grasmader K, et al. Population pharmacokinetic analysis of mirtazapine. *Eur J Clin Pharmacol* 2004; 60:473–480.
24. Carrillo JA, et al. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. *J Clin Psychopharmacol* 2003; 23:119–127.
25. Lowe EJ, et al. Impact of tobacco smoking cessation on stable clozapine or olanzapine treatment. *Ann Pharmacother* 2010; 44:727–732.
26. Horvat M, et al. Association of smoking cigarettes, age, and sex with serum concentrations of olanzapine in patients with schizophrenia. *Biochem Med (Zagreb)* 2023; 33:030702.
27. Schoretsanitis G, et al. Effect of smoking on risperidone pharmacokinetics – a multifactorial approach to better predict the influence on drug metabolism. *Schizophr Res* 2017; 185:51–57.
28. Schoretsanitis G, et al. Lack of smoking effects on pharmacokinetics of oral paliperidone—analysis of a naturalistic therapeutic drug monitoring sample. *Pharmacopsychiatry* 2021; 54:31–35.
29. Ishida M, et al. Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. *Int Clin Psychopharmacol* 1995; 10:143–146.
30. Ereshefsky L, et al. Pharmacokinetic factors affecting antidepressant drug clearance and clinical effect: evaluation of doxepin and imipramine – new data and review. *Clin Chem* 1988; 34:863–880.
31. Lundstrøm NH, et al. The effect of smoking on the plasma concentration of tricyclic antidepressants: a systematic review. *Acta Neuropsychiatr* 2022; 34:1–9.
32. Jann MW, et al. Clinical pharmacokinetics of the depot antipsychotics. *Clin Pharmacokinet* 1985; 10:315–333.
33. Jorgensen A, et al. Zuclopenthixol decanoate in schizophrenia: serum levels and clinical state. *Psychopharmacology (Berl)* 1985; 87:364–367.
34. Blacker CJ. Clinical issues to consider for clozapine patients who vape: a case illustration. *Focus (Am Psychiatr Publ)* 2020; 18:55–57.
35. Montville DJ, et al. Fluctuation between cigarette smoking and use of electronic nicotine delivery systems: impact on clozapine concentrations and clinical effect. *Ment Health Clin*

2021; 11:365-368.

Revision #1

Created 2026-01-04 20:18:12 UTC by Omar Ayman

Updated 2026-01-04 20:18:12 UTC by Omar Ayman